JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prognostic implications of immune classification based on PD-L1 expression and tumor-infiltrating lymphocytes in endocervical adenocarcinoma

  • 0Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Translational Oncology +

|

December 30, 2024

|

December 30, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Endocervical adenocarcinoma (ECA) subtypes have distinct immune microenvironments. Tumor microenvironment immune types (TMIT) classification, particularly TMIT I in non-HPVA cases, shows prognostic value and may predict immunotherapy response.

Area Of Science

  • Oncology
  • Immunology
  • Pathology

Background

  • Endocervical adenocarcinoma (ECA) incidence is rising, with distinct human papillomavirus-associated (HPVA) and non-HPVA (NHPVA) subtypes.
  • Varied pathological features and clinical behaviors necessitate evaluating immune microenvironments.
  • Tumor microenvironment immune types (TMIT) offer a classification framework.

Purpose Of The Study

  • To classify ECA into TMIT based on PD-L1 and CD8+ tumor-infiltrating lymphocytes (TILs).
  • To analyze the prognostic significance of these TMIT classifications.
  • To identify potential predictive markers for immunotherapy response.

Main Methods

  • Surgically resected ECA samples (n=540) were classified into HPVA and NHPVA subgroups.
  • Immunohistochemistry assessed tumor-infiltrating immune markers.
  • ECA were categorized into four TMIT based on PD-L1 and CD8+ TILs expression.

Main Results

  • High CD8+ TILs expression correlated with improved disease-free survival (DFS) and overall survival (OS).
  • TMIT I (high PD-L1, high CD8+ TILs) showed denser immune infiltration.
  • In NHPVA, TMIT was significantly associated with DFS and OS, with TMIT I indicating a favorable prognosis.

Conclusions

  • TMIT classification holds significant prognostic value in ECA.
  • The TMIT I group within the NHPVA population may benefit from PD-L1/PD-1 blockade immunotherapies.
  • TMIT has potential utility in clinical stratification and guiding therapeutic decisions.

Keywords: